WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006016707) PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/016707    International Application No.:    PCT/JP2005/014969
Publication Date: 16.02.2006 International Filing Date: 10.08.2005
IPC:
A61K 31/4152 (2006.01), A61P 25/00 (2006.01)
Applicants: MITSUBISHI PHARMA CORPORATION [JP/JP]; 6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 5410046 (JP) (For All Designated States Except US).
YUKI, Satoshi [JP/JP]; (JP) (For US Only).
NAKANO, Takuma [JP/JP]; (JP) (For US Only).
SUZUKI, Hiroko [JP/JP]; (JP) (For US Only)
Inventors: YUKI, Satoshi; (JP).
NAKANO, Takuma; (JP).
SUZUKI, Hiroko; (JP)
Agent: TAKAYANAGI, Masau; MITSUBISHI PHARMA CORPORATION, Intellectual Property Department, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 1038405 (JP)
Priority Data:
2004-233635 10.08.2004 JP
Title (EN) PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS
(FR) COMPOSES DE PYRAZOLONE UTILES DANS LE TRAITEMENT DE TROUBLES CEREBROVASCULAIRES ASSOCIES A L'ACCIDENT ISCHEMIQUE CEREBRAL
Abstract: front page image
(EN)A drug including edaravone for the treatment of cerebrovascular disorders associated with insufficient cerebral circulation such as ischemic stroke, which comprises a pharmaceutically effective amount of a pyrazolone compound of structural Formula (I): or a pharmaceutically acceptable salt thereof, or a pseudo-polymorphic form thereof, administered at a controlled dose so that the plasma concentration of unchanged form is kept constant for a predetermined period of time and so that the compound may exhibit a higher effect.
(FR)L'invention concerne un médicament destiné au traitement de troubles cérébrovasculaires à une circulation cérébrale insuffisante tels que l'accident ischémique cérébral, lequel contient une dose pharmaceutique efficace d'un composé de pyrazolone ayant la formule structurale (I) ou bien un sel pharmaceutiquement acceptable de celui-ci, ou une forme pseudo-polymorphe de celui-ci, administré à une dose réglée de sorte que la concentration dans le plasma de la forme non modifiée est gardée constante pendant une durée prédéterminée, et de telle sorte que le composé peut présenter un effet supérieur.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)